NewLink jump-starts a Zika vaccine program as virus spreads
NewLink Genetics, which partnered with Merck on a promising Ebola program, has joined the incipient race to find a vaccine that can be used to combat the recent spread of the Zika virus.
Merck's Ebola vaccine is 100% successful in interim Phase III results
Merck's Ebola vaccine, in development alongside NewLink Genetics, protected 100% of patients from contracting the virus in interim results from an ongoing study, giving rise to hopes it can help prevent future outbreaks.
Without convincing data to prove a win for NewLink Genetics' late-stage cancer vaccine, it will go full steam ahead on its Phase III trial, the company announced Monday. The IMPRESS trial for algenpantucel-L--or HyperAcute pancreas--will continue with no changes following the second planned interim analysis for the trial.
NewLink shares plunge as cancer vaccine passes another interim analysis
NewLink Genetics rattled investors after the markets closed on Monday, saying it will need to cruise past its second planned interim analysis for a late-stage cancer vaccine without any change to the trial. No news is bad news as far as the market is concerned.
GlaxoSmithKline's Ebola candidate will be the first of several experimental vaccines to undergo large-scale clinical trials. On Friday, the company shipped an initial batch of 300 vials of the vaccine, ChAd3, to Liberia, one of the main countries affected by Ebola.
The previously suspended Swiss trial of Merck and NewLink's experimental Ebola vaccine is back on, but this time at a lower dose.
Merck, NewLink nab $30M from BARDA to help manufacture Ebola vax
NewLink Genetics and its new partner Merck have gotten a $30 million grant from the U.S. government to help with manufacturing and development of the Ebola vaccine the two are working on.
Merck hits a hiccup with its new Ebola vaccine
Investigators have suspended a Phase I study of NewLink Genetics' Ebola virus vaccine just weeks after Merck stepped in to license it, citing a safety issue that could delay the pharma giant's plans to quickly ramp up production.
Just days after GlaxoSmithKline and the NIH's National Instite of Allergy and Infectious Diseases announced Phase I success for their investigative Ebola vaccine, Merck and NewLink Genetics have their own positive news to report.
Merck steps into Ebola vaccine race with NewLink rights deal
Merck has snapped up the exclusive rights to NewLink Genetics' Ebola vaccine, which is being rushed into a Phase III study as part of a global effort to head off an outbreak in West Africa.